In Madrid, at the crossroads of science and human longing, Novo Nordisk offered a glimpse of what medicine has long sought: a pill that meaningfully reduces weight. Amycretin, targeting two appetite-regulating hormones at once, produced up to 13 percent body weight loss over twelve weeks in early human trials — a result that dwarfs the placebo and arrives in a form people can swallow rather than inject. It is a first step, not a destination, but in the slow arc of pharmaceutical progress, first steps carry their own significance.
Novo Nordisk's oral weight loss drug Amycretin shows 13% body weight reduction in early trial
Weight loss had not plateaued by trial's end
Mark
Why does it matter that this is a pill instead of an injection? People use injections for insulin all the time.
Mimi
True, but insulin is something people with diabetes have to use regardless. Weight loss drugs are different—they're optional, and they're long-term. Taking a needle once a week or once a month for years is a real barrier for some people. A pill removes that friction.
Mark
But the weight loss numbers—13 percent in twelve weeks—how does that compare to what's already available?
Mimi
The source doesn't make that comparison, which is telling. We don't know yet. GLP-1 drugs like semaglutide produce similar or better results, but they're injections. This trial wasn't designed to compare amycretin head-to-head with existing treatments. It was just asking: is this safe, and does it do anything?
Mark
The fact that weight loss hadn't plateaued—what does that really mean?
Mimi
It means the body hadn't reached an equilibrium yet. The participants were still losing weight at week twelve. In theory, if they'd kept taking it, they might have lost more. But we don't know if that trend continues indefinitely or if it levels off at some point. That's what the longer studies will need to show.
Mark
What worries you about this drug?
Mimi
The gastrointestinal side effects—nausea and vomiting—are real, even if they're mild to moderate. People stop taking medications that make them feel sick. And we're still in the dark about long-term safety. Three months is not a long time.
Mark
So this is hype?
Mimi
Not hype, exactly. It's genuine early progress. But it's also very early. The difference between a promising phase-one result and a drug that actually helps people is enormous. This clears one hurdle. Many more remain.
O Pulso
- The weight loss drug landscape has long been dominated by injections — amycretin's emergence as an oral option disrupts that norm and raises patient expectations.
- A 13% body weight reduction in just twelve weeks, against a placebo's 1.1%, signals a potent biological effect that the research community cannot easily dismiss.
- Side effects — mostly nausea and vomiting — mirror those of existing drugs in the class, suggesting familiar trade-offs rather than alarming new risks.
- Weight loss was still accelerating at the trial's end, leaving open the tantalizing and unanswered question of how far the effect might extend over months or years.
- The trial was small and designed for safety, not proof of superiority — larger, longer studies must now carry the burden of confirming what this early signal suggests.
In Madrid, at the crossroads of science and human longing, Novo Nordisk offered a glimpse of what medicine has long sought: a pill that meaningfully reduces weight. Amycretin, targeting two appetite-regulating hormones at once, produced up to 13 percent body weight loss over twelve weeks in early human trials — a result that dwarfs the placebo and arrives in a form people can swallow rather than inject. It is a first step, not a destination, but in the slow arc of pharmaceutical progress, first steps carry their own significance.
At a diabetes research conference in Madrid, Novo Nordisk presented early results for amycretin — a once-daily pill that targets both amylin and GLP-1 hormone systems to suppress appetite. The significance lies not only in what the drug does, but in how it is taken: current medications working on similar pathways require injections, and for people managing weight over years, a tablet represents a meaningful shift.
The trial enrolled adults with BMIs between 25 and 40, without diabetes, across multiple dose levels over twelve weeks. Results tracked closely with dose — participants on 50 milligrams daily lost an average of 10.4 percent of body weight, while those on the maximum 100-milligram dose lost 13.1 percent. The placebo group lost just over 1 percent. Side effects were largely mild gastrointestinal symptoms, consistent with similar drugs, and no serious safety concerns emerged.
Perhaps the most striking observation was that weight loss had not leveled off by the trial's end — participants were still losing weight at the final measurement, leaving open the question of what extended use might achieve. Researchers were candid about the study's limits: it was a first-in-human trial, built to test safety rather than establish superiority over existing treatments. Larger and longer studies remain necessary.
Amycretin occupies that charged space between early promise and genuine uncertainty. The mechanism is credible, the initial safety profile acceptable, and the weight loss signal real — but whether this pill will one day reach patients and prove itself against injections that already work is a question only time and further research can answer.
At a diabetes research conference in Madrid this week, Novo Nordisk presented results from an early trial of a drug that does something the weight loss world has not yet managed: it comes as a pill. The drug, called amycretin, produced weight loss of up to 13 percent over three months in people taking the highest dose—a result that substantially outpaced the placebo group, which lost just over 1 percent in the same period.
The appeal is straightforward. Current weight loss medications that work on similar biological pathways require injections. Amycretin targets two hormone systems at once—amylin and GLP-1—both of which regulate appetite and hunger. By combining both mechanisms into a single oral molecule, the drug offers what amounts to a convenience advantage: a tablet instead of a needle. For people managing weight loss over months or years, that difference matters.
The trial itself was small and early-stage, the kind of study designed to test whether a drug is safe enough to move forward, not whether it works better than existing treatments. Researchers at a clinical research unit in the United States enrolled adults with BMI between 25 and 40 who did not have diabetes. Some received amycretin in escalating doses over twelve weeks; others received placebo. The drug was tested at multiple dose levels, ranging from 1 milligram daily up to 100 milligrams daily (given as two 50-milligram doses).
The weight loss results tracked with dose. People taking 50 milligrams once daily lost an average of 10.4 percent of their body weight. Those on the maximum dose of 100 milligrams daily lost 13.1 percent. The side effects were mostly mild to moderate gastrointestinal symptoms—nausea and vomiting—consistent with what researchers see with other drugs in this class. No serious safety signals emerged.
One detail stood out to the researchers: weight loss had not plateaued by the end of the twelve-week trial. Participants were still losing weight at the final measurement, suggesting that longer treatment might produce even greater reductions. That observation opens a question the current data cannot answer: how much weight could people lose if they continued the drug for six months, a year, or longer?
The researchers acknowledged the obvious limitation. This was a first-in-human trial—the earliest stage of testing in people. It was small, short, and designed to establish safety, not efficacy. Larger, longer studies would be needed to confirm that amycretin works as well as existing injectable treatments, to understand its long-term safety profile, and to determine which patients benefit most. The company has not yet announced plans for those next-phase trials.
For now, amycretin exists in that narrow space where early promise meets genuine uncertainty. The mechanism is sound. The initial safety profile is acceptable. The weight loss signal is real. But whether this drug will eventually reach patients, and whether it will prove superior to injections that already work, remains an open question. What is clear is that the pharmaceutical industry is still searching for the weight loss treatment that combines effectiveness with the simplicity of a daily pill—and this early result suggests the search may not be over.
Citações Notáveis
A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity.— Study authors
Larger and longer studies are needed to fully assess the drug's safety profile and potential.— Study authors
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Health & Medicine